ALNY - アルナイラム・ファ―マシュ―ティカルズ (Alnylam Pharmaceuticals Inc.) アルナイラム・ファ―マシュ―ティカルズ

 ALNYのチャート


 ALNYの企業情報

symbol ALNY
会社名 Alnylam Pharmaceuticals Inc (アルナイラム・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルナイラム・ファーマシューティカルズ(Alnylam Pharmaceuticals Inc.)はリボ核酸干渉法(RNAi)に基づく治療薬を開発する生物医薬品会社である。同社の「Alnylam 5x15」は遺伝的疾患の治療向けに、リボ核酸干渉法を用いた新規治療薬の開発及び商品化に注力する。同社の臨床または前臨床開発段階の中核プログラムには、トランスサイレチン媒介性アミロイドーシス(ATTR)の治療向けの「ALN-TTR」、血友病の治療向けの「ALN-APC」、重度の高コレステロール血症の治療向けの「ALN-PCS」、不応性貧血の治療向けの「ALN-HPN」、並びにベータサラセミア及び鎌状赤血球貧血症を含む異常ヘモグロビン症の治療向けの「ALN-TMP」が含まれる。パートナーベースのプログラムとしては、同社は呼吸器合胞体ウイルス(RSV)感染症の治療向けの「ALN-RSV01」、肝癌の治療向けの「ALN-VSP」、並びにハンチントン病(HD)の治療向けの「ALN-HTT」を含む臨床または前臨床開発段階のプログラムを3つ有する。   アルナイラム・ファ―マシュ―ティカルズは米国のバイオテクノロジ―企業。2002年の創業以来、一貫してRNAi(各種疾患の原因となるタンパク質を作り出す遺伝子に直接・選択的に作用する特徴を有する)技術を基盤とした医薬品研究開発を行い、RNAi医薬の研究・開発に必要な多くの特許、技術を保持する。本社はマサチュ―セッツ州ケンブリッジ。   Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
本社所在地 300 Third Street Cambridge MA 02142 USA
代表者氏名 Michael W. Bonney マイケル・W・ボニー
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-551-8200
設立年月日 37742
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 749人
url www.alnylam.com
nasdaq_url https://www.nasdaq.com/symbol/alny
adr_tso
EBITDA EBITDA(百万ドル) -600.14400
終値(lastsale) 83.21
時価総額(marketcap) 8376427179.52
時価総額 時価総額(百万ドル) 8222.408
売上高 売上高(百万ドル) 106.82600
企業価値(EV) 企業価値(EV)(百万ドル) 6804.742
当期純利益 当期純利益(百万ドル) -570.73800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alnylam Pharmaceuticals Inc. revenues increased 48% to $51.8M. Net loss before extraordinary items increased 35% to $305.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $40.5M to $87.2M (expense).

 ALNYのテクニカル分析


 ALNYのニュース

   Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results  2021/07/21 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2021 on Tuesday, August 3, 2021, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2021 results as well as expectations for the future via conference call on Tuesday, August 3, 2021 at 8:30 am ET. To access the call, ple
   The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay  2021/07/21 11:52:07 Business Insider Markets
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals, Inc.
   Thinking about trading options or stock in Alnylam Pharmaceuticals, Tesla, Cintas, GameStop, or Microsoft?  2021/07/19 13:31:00 Benzinga
NEW YORK , July 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALNY, TSLA, CTAS, GME, and MSFT. Full story available on Benzinga.com
   Alnylam Pharmaceuticals Inc (ALNY) EVP, Chief Legal Officer Laurie Keating Sold $1. ...  2021/07/15 04:15:09 GuruFocus
Related Stocks: ALNY ,
   Cohen Lawrence B Buys BlackRock Inc, Alnylam Pharmaceuticals Inc, Sells T. ...  2021/07/14 20:38:05 GuruFocus
Related Stocks: BLK , ALNY , VHT , CL , BA ,
   Alnylam Pharma Says FDA Accepts NDA Vutrisiran To Treat Polyneuropathy Of HATTR Amyloidosis  2021/06/24 11:42:57 RTT News
RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
   FDA accepts Alnylam''s vutrisiran application for hereditary ATTR amyloidosis  2021/06/24 11:18:12 Seeking Alpha
   Alnylam Pharmaceuticals divulges ATXN3-targeting ds-siRNAs  2021/06/18 13:58:11 BioWorld
   Novartis AG Consensus Indicates Potential 12.1% Upside  2021/06/18 06:54:25 DirectorsTalk
Novartis AG found using ticker (NVS) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 108.5 and 103 with the average target price sitting at 105.13. Now with the previous closing price of 93.79 this indicates there is a potential upside of 12.1%. There is a 50 day moving average of 88.94 while the 200 day moving average is 89.43. The company has a market capitalisation of $213,642m. Visit the company website at: /> [stock_market_widget type="chart" symbol="NVS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.
   Novartis AG Consensus Indicates Potential 18.3% Upside  2021/06/04 13:17:04 DirectorsTalk
Novartis AG found using ticker (NVS) now have 4 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 108.5 and 103 calculating the average target price we see 105.13. Given that the stocks previous close was at 88.89 this now indicates there is a potential upside of 18.3%. There is a 50 day moving average of 87.76 while the 200 day moving average is 89.13. The market cap for the company is $201,251m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="NVS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.
   BMO Capital Stick to Their Hold Rating for Alnylam Pharmaceuticals By Investing.com  2021/04/20 13:46:38 Investing.com
BMO Capital Stick to Their Hold Rating for Alnylam Pharmaceuticals
   Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine  2021/04/01 12:55:27 Benzinga
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY ) has announced that trial results from the ILLUMINATE-A Phase 3 study evaluating lumasiran for the treatment of primary hyperoxaluria type 1 (PH1). The results were published online in The New England Journal of Medicine. Lumasiran an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) In November last year, Oxlumo (lumasiran) was approved by the FDA to treat PH1 … Full story available on Benzinga.com
   Global Oligonucleotide Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes - ResearchAndMarkets.com  2021/03/23 14:36:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global oligonucleotide therapy market is expected to decline from $0.9 billion in 2019 to $0.88 billion in 2020 at a compound annual growth rate (CAGR) of -2.1%. Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck
   Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021  2021/03/23 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 9-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, at the American Academy of Neurology (AAN) Virtual Annual Meeting, being held April 17-22. The Company previously announced positive t
   Transthyretin Amyloidosis Treatment Market - Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.  2021/03/08 06:30:34 OpenPR
Transthyretin Amyloidosis Treatment Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Transthyretin Amyloidosis Treatment industry overview and then goes into each and every detail. Transthyretin Amyloidosis Treatment Market Report contains in depth

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルナイラム・ファ―マシュ―ティカルズ ALNY Alnylam Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)